AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CARL

Bertolini Jeffrey sold $4K of CARL

Bertolini Jeffrey (Chief Operating Officer) sold 243 shares of CARLSMED, INC. (CARL) at $15.80 on 2026-10-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bertolini Jeffrey
Published Nov 2, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CARL
Neutral
high confidence
Mentioned
$CARL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CARLNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect the stock price materially.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or earnings that may affect insider behavior.

Relevance 2/10Novelty 2/10Timing: filing today

Background

Form 4 filing reports insider transactions required by SEC, providing transparency on insider holdings.

Company-level read

Ticker impact

$CARLNeutralHigh confidence
Context

Chief Operating Officer sold 243 shares at $15.80 each, total $3,839, via a 10b5-1 plan.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The sale is small relative to holdings and typical for insiders, unlikely to move price significantly.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the insider is reducing exposure, could signal concerns, but size is too small to act on.

Key entities

  • Person
    Bertolini Jeffrey

    Chief Operating Officer of Carlsmed, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CARL insider trading history →

Related articles

$CARLHigh

Carlsmed (CARL) Q3 2026 Earnings Call Transcript

Carlsmed (CARL) reported 65% revenue growth in Q3 2026, raising full-year guidance to $78M-$80M. The company launched new products and expects 2027 catalysts. Management updates include new COO, CFO, and Chief Product & AI Officer. Clinical data shows reduced reoperation rates, and new reimbursement codes may boost hospital adoption.

finance.yahoo.com
$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

finance.yahoo.com
$CARLHigh

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (

SEC EDGAR 8-K